Dyadic International, Inc., a global biotechnology company, has announced a strategic rebrand to Dyadic Applied BioSolutions. This change reflects the company's focus on commercializing non-therapeutic proteins using its proprietary C1 and Dapibus™ gene expression platforms. The rebrand marks a pivotal step in transitioning from a research-driven organization to a commercially focused enterprise, emphasizing applied biotechnology solutions for various industries.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.